Cytomed Therapeutics H1 2026 net loss narrows 20.1% to S$1.79m
Cytomed Therapeutics reported a net loss of S$1.79 million for the six months ended June 30, 2026, a 20.1% decrease from the prior year, driven by lower other expenses, including consultancy costs, and gains on forex and warrant liabilities. Other income declined due to lower interest and research income.